The ROE as of September 2024 (TTM) for ImmunityBio, Inc. (IBRX) is 100.06%

According to ImmunityBio, Inc.’s latest financial reports and current stock price. The company's current ROE is 100.06%. This represents a change of 293.85% compared to the average of 25.41% of the last 4 quarters.

ImmunityBio, Inc. (IBRX) Historical ROE (quarterly & annually)

How has IBRX ROE performed in the past?

The mean historical ROE of ImmunityBio, Inc. over the last ten years is 16.32%. The current 100.06% ROE has changed 513.11% with respect to the historical average. Over the past ten years (40 quarters), IBRX's ROE was at its highest in in the December 2020 quarter at 56.57%. The ROE was at its lowest in in the June 2015 quarter at -66.85%.

ImmunityBio, Inc. (IBRX) ROE by Quarter and Year

Discovering the peaks and valleys of ImmunityBio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

ImmunityBio, Inc. (IBRX) Average ROE

How has IBRX ROE performed in the past?

The current ROE of ImmunityBio, Inc. (IBRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

ImmunityBio, Inc. (IBRX) ROE vs. Peers

How is IBRX’s ROE compared to its peers?

ImmunityBio, Inc.’s ROE is less than BioLineRx Ltd. (0%), greater than Ardelyx, Inc. (-225.62%), greater than Lexicon Pharmaceuticals, Inc. (-39.73%), less than Seres Therapeutics, Inc. (73.27%), less than eFFECTOR Therapeutics, Inc. (313.56%), less than Protalix BioTherapeutics, Inc. (2.18%), greater than PDS Biotechnology Corporation (-45.15%), greater than aTyr Pharma, Inc. (-137.06%), greater than Elevation Oncology, Inc. (-56.83%), greater than CureVac N.V. (-57.97%), greater than Reata Pharmaceuticals, Inc. (-56.93%), less than Krystal Biotech, Inc. (19.32%), less than Vir Biotechnology, Inc. (13.36%), greater than Propanc Biopharma, Inc. (-30.93%), less than Viking Therapeutics, Inc. (70.39%), greater than TG Therapeutics, Inc. (-15.05%), greater than X4 Pharmaceuticals, Inc. (-38.21%), less than Madrigal Pharmaceuticals, Inc. (32.93%), greater than null (-95.61%),

Build a custom stock screener for ImmunityBio, Inc. (IBRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmunityBio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ImmunityBio, Inc. (IBRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ImmunityBio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.